Morgan Stanley
TAK icon

Morgan Stanley’s Takeda Pharmaceutical TAK Stock Holding History

Morgan Stanley’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120M Buy
6,469,600
+96,398
+2% +$1.69M 0.01% 1290
2025
Q4 		$99.4M Sell
6,373,202
-1,317,213
-17% -$18.8M 0.01% 1453
2025
Q3 		$113M Buy
7,690,415
+70,825
+0.9% +$1.05M 0.01% 1307
2025
Q2 		$118M Buy
7,619,590
+1,917,066
+34% +$28.3M 0.01% 1191
2025
Q1 		$84.8M Buy
5,702,524
+101,699
+2% +$1.42M 0.01% 1373
2024
Q4 		$74.2M Buy
5,600,825
+245,928
+5% +$3.38M 0.01% 1483
2024
Q3 		$76.1M Buy
5,354,897
+367,945
+7% +$5.22M 0.01% 1454
2024
Q2 		$64.5M Sell
4,986,952
-8,671
-0.2% -$115K 0.01% 1509
2024
Q1 		$69.4M Sell
4,995,623
-4,699,447
-48% -$68.3M 0.01% 1463
2023
Q4 		$138M Buy
9,695,070
+4,461,789
+85% +$63.3M 0.01% 1412
2023
Q3 		$81M Buy
5,233,281
+455,729
+10% +$7.05M 0.01% 1202
2023
Q2 		$75.1M Buy
4,777,552
+197,001
+4% +$3.23M 0.01% 1265
2023
Q1 		$75.5M Buy
4,580,551
+57,112
+1% +$910K 0.01% 1230
2022
Q4 		$70.6M Sell
4,523,439
-99,568
-2% -$1.39M 0.01% 1247
2022
Q3 		$60M Buy
4,623,007
+379,182
+9% +$5.27M 0.01% 1190
2022
Q2 		$59.6M Buy
4,243,825
+3,920,647
+1,213% +$56M 0.01% 1253
2022
Q1 		$4.63M Sell
323,178
-377,433
-54% -$5.54M ﹤0.01% 3773
2021
Q4 		$9.55M Sell
700,611
-1,243,352
-64% -$17.4M ﹤0.01% 2996
2021
Q3 		$31.8M Sell
1,943,963
-82,419
-4% -$1.38M ﹤0.01% 1649
2021
Q2 		$34.1M Sell
2,026,382
-120,801
-6% -$2.06M ﹤0.01% 1614
2021
Q1 		$39.2M Buy
2,147,183
+183,641
+9% +$3.3M 0.01% 1358
2020
Q4 		$35.7M Sell
1,963,542
-54,776
-3% -$961K 0.01% 1343
2020
Q3 		$36M Buy
2,018,318
+44,163
+2% +$804K 0.01% 1083
2020
Q2 		$35.4M Buy
1,974,155
+398,173
+25% +$7.15M 0.01% 1038
2020
Q1 		$23.9M Buy
1,575,982
+842,734
+115% +$15.3M 0.01% 1156
2019
Q4 		$14.5M Buy
733,248
+161,005
+28% +$3.08M ﹤0.01% 1983
2019
Q3 		$9.84M Sell
572,243
-882,166
-61% -$15.3M ﹤0.01% 2147
2019
Q2 		$25.7M Buy
1,454,409
+163,572
+13% +$2.98M 0.01% 1299
2019
Q1 		$26.3M Buy
1,290,837
+1,251,913
+3,216% +$25.2M 0.01% 1249
2018
Q4 		$655K Buy
+38,924
New +$657K ﹤0.01% 4609

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley's TAK Position: Q1 2026 in Review

Morgan Stanley increased its Takeda Pharmaceutical (TAK) stake by 1.5% in Q1 2026, buying an estimated $1.69M and bringing the position to 6,469,600 shares worth $120M. The position accounts for 0.01% of the portfolio, ranked #1290.

Morgan Stanley first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $138M in Q4 2023. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Morgan Stanley held 6,469,600 shares of Takeda Pharmaceutical worth $120M as of Q1 2026.
  • Morgan Stanley bought 96,398 Takeda Pharmaceutical shares in Q1 2026, an estimated $1.69M.
  • Takeda Pharmaceutical made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1290 holding.
  • Morgan Stanley first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
  • Morgan Stanley's Takeda Pharmaceutical position peaked at $138M in Q4 2023.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.